Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, 52-weeks Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 mL Pre-filled Syringes (300 mg) in Adult Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2022
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms ALLURE
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 25 Apr 2021 Primary endpoint (Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment) has been met, as per Results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
- 25 Apr 2021 Primary endpoint (Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment) has been met, as per Results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
- 25 Apr 2021 Results presented at the American Academy of Dermatology Virtual Meeting Experience 2021